国家医保药品目录与国外药品目录对肠外营养药品管理的比较

Management comparision of parenteral nutrition medicines between national medical insurance drug catalogue and foreign drug catalogues

目的了解肠外营养药品在《国家基本医疗保险、工伤保险和生育保险药品目录(2020年版)》(国家医保目录2020版)与国外药品目录的收录情况,为我国该类药品的遴选与管理提供参考。方法收集国家医保目录第2020版、澳大利亚药品福利计划、英国国家处方集第79版、WHO基本药物清单第21版4个药品目录肠外营养药品的收录情况,考察其收录异同。结果澳大利亚药品福利计划未查询到肠外营养药品,WHO基本药物清单第21版仅收录葡萄糖,国家医保目录2020版收录肠外营养药品情况与英国国家处方集第79版相近,未纳入品种主要为含ω-3鱼油脂肪乳的复方制剂。结论国家医保目录2020版对肠外营养药品涵盖范围较广,但命名方面仍需进一步完善。

Objective To investigate the inclusion of parenteral nutrition medicines in medical insurance catalogue at home and abroad,and to provide references for the selection and management of such medicines in China. Methods The inclusion of parenteral nutrition drugs in four drug catalogues,namely national medical insurance catalogue 2020,Australian drug welfare plan,British National Formulary 79 edition and WHO essential drug list 21 edition,were collected,and their similarities and differences were investigated. Results Parenteral nutrition medicines were not included in Australian drug welfare plan. WHO essential drug list 21 edition only containedglucose. Nationalmedical insurance catalogue containsed parenteral nutrition drugs similar to British National Formulary 79 deition,most of varieties not included in were compound preparations containing ω-3 fatty acid.Conclusion National basic hospitalization insurance catalog 2020 covers a wide range of parenteral nutrition medicines,but the nomenclature still needs further improvement.